Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc.
1:16-cv-00465
Overview
Parties
Defendant
Hisamitsu Pharmaceutical Co., Inc. NPE (University / Research)
Represented By
0 Attorneys ListedActavis Laboratories UT, Inc. Operating Company
Represented By
2 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Plaintiff
Noven Pharmaceuticals, Inc. Operating Company
Represented By
3 Attorneys ListedPolsinelli PC
222 Delaware Avenue, Suite 1101, Wilmington, DE 19801
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 19 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,231,906 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| π PCT International (WIPO) | WO 2010006143 A2 | PCT World Application | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 15,173,544 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 3,173,078 A1 | European Counterpart (EP) | View Official Patent → |
| π°π· South Korea | KR 1020117002 | South Korea Counterpart | View Official Patent → |
| π°π· South Korea | KR 2011003933 | South Korea Counterpart | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 9,790,211 | European Counterpart (EP) | View Official Patent → |
| πͺπΊ European Patent Office (UPC States) | EP 2,310,001 B1 | European Counterpart (EP) | View Official Patent → |
| π―π΅ Japan | JP 2011517610 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 5676440 B2 | Japan Counterpart | View Official Patent → |
| π¨π¦ Canada | CA 2729950 A | Canada Counterpart | View Official Patent → |
| πΊπΈ United States | US 9,730,900 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,724,310 B2 | US Continuation / Sibling | View Official Patent → |
| π―π΅ Japan | JP 2014194881 A | Japan Counterpart | View Official Patent → |
| π―π΅ Japan | JP 6118774 B2 | Japan Counterpart | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8231906
Transdermal estrogen device and delivery
|
Filed: 2008-07-10
Issued: 2012-07-31
|
Active (3.6 yrs remaining)
+724d PTA
Expires: 2030-07-04
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+724 days) / Cellect Scrutiny β Over 724 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings